Well it's true, we will need a little bit of luck but the phase 2 trial was convincingly on the side of success. But here's the thing. All of the VEGF-A inhibitors run into the same limitations to efficacy after 6m of treatment, and that is up-regulation of the unblocked Isoform pathways. So if that's all they've got, then all they're selling is a more convenient way to give it. And your entitled to your opinion that "combination therapy isn't it" but if it's given in a single injection, it makes no difference to the clinician and the patient won't even be aware. But in a market worth $11b a year, having the best treatment available will be worth pursuing. These two year trials with almost a thousand patients in each trial will be absolutely definitive. We'll know for sure if the combination is better than a VEGF-A inhibitor or even Afibercept, and whether or not that effect lasts.
- Forums
- ASX - By Stock
- OPT
- Ann: Opthea Finalizes Ph 3 Study Designs and Startup Activities
Ann: Opthea Finalizes Ph 3 Study Designs and Startup Activities, page-42
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
37.5¢ |
Change
-0.005(1.32%) |
Mkt cap ! $409.3M |
Open | High | Low | Value | Volume |
38.0¢ | 39.0¢ | 37.0¢ | $728.0K | 1.935M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
12 | 144551 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 6300 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 144551 | 0.370 |
4 | 79072 | 0.365 |
9 | 267935 | 0.360 |
2 | 3450 | 0.355 |
10 | 221847 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 6300 | 1 |
0.380 | 108918 | 2 |
0.385 | 10572 | 1 |
0.390 | 50000 | 1 |
0.400 | 16544 | 4 |
Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |